Phathom Pharmaceuticals, Inc. announced multiple executive appointments. As previously announced as part of the Company's
succession plan, Terrie Curran, former President of the Global Inflammation and Immunology (I&I) Franchise at Celgene, now joins Phathom as Chief Executive Officer. Founding CEO David Socks transitions to interim Chief Financial Officer and remains a member of the Board of Directors. In addition to Ms. Curran, also joining the Phathom leadership team are Eckhard Leifke, MD, as Chief Medical Officer; Joseph Hand, JD, as Chief Administrative Officer; and Larry Miller, JD, as General Counsel. Phathom also announced that Asit Parikh, MD, PhD has replaced Chris Slavinsky on the Company's Board of Directors. Ms. Curran has more than 20 years of experience in the biopharmaceutical industry. She has served as President, Global Inflammation and Immunology (I&I) Franchise and as a member of the Executive Committee at Celgene Corporation since 2017. Dr. Leifke joins Phathom from Omeros where he served as Chief Medical Officer. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities - Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development - Diabetes. Mr. Hand joins Phathom from Celgene, where he most recently served as Executive Vice President, Global Human Resources and Corporate Services and a member of its Executive Committee. In that capacity, he was responsible for all employee-related activities including talent development, recruiting, and compensation and benefits. Mr. Miller joins Phathom as General Counsel from Cyclerion Therapeutics where he served as General Counsel and Secretary. Prior to Cyclerion, he served as Senior Vice President, General Counsel and Secretary of Blue Buffalo where he led all legal activities including those related to the $8 billion acquisition by General Mills. In addition to the executive appointments, Dr. Parikh joins Phathom's Board of Directors as Chris Slavinsky steps down following his departure from Takeda to join Prometheus Biosciences. Dr. Parikh is currently Senior Vice President and Head of the Gastroenterology Therapeutic Area Unit at Takeda.